← back to search

Xuefeng Xia

BGI Group (China) · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, and Cancer Genomics and Diagnostics.
h-index
42
citations
7,368
works
267
NIH funding
primary concept
Biology
email

Recent publications

Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.
2025cited by 4position: contributordoi
Supplementary Figure S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S3 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S3 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Data from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S7 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S8 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Figure S7 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025cited by 0position: contributordoi
Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
2023cited by 0position: contributordoi
Table S12 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Figure S4 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Figure S6 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Data from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Figure S5 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Figure S6 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
2023cited by 0position: contributordoi
Figure S3 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Supplementary Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
2023cited by 0position: contributordoi
Supplementary legend from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Table S1 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi
Table S13 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 84 papers (2021–2025) · 81 papers (2022–2025) · 49 papers (2022–2023)Qian Li · First Affiliated Hospital of Xi'an Jiaotong University49 papers (2022–2023) · 49 papers (2022–2023)Shawna M. Hubert · University of Chinese Academy of Sciences49 papers (2022–2023)Qing Zhou · Lanzhou University33 papers (2020–2025)Yi‐Long Wu · China Agricultural University33 papers (2020–2025)Hai‐Yan Tu · Jiangnan University33 papers (2020–2025) · 32 papers (2022–2025) · 32 papers (2022–2025) · 32 papers (2022–2025) · 32 papers (2022–2025) · 32 papers (2022–2025) · 32 papers (2022–2025)Hong-Hong Yan · Guangdong Provincial People's Hospital32 papers (2022–2025) · 32 papers (2022–2025)Wen‐Zhao Zhong · Sun Yat-sen University Shenzhen 510275 China +86203933215318 papers (2022–2025)Song Dong · Army Medical University17 papers (2025–2025) · 17 papers (2025–2025)